Delayed treatment in CH significantly impairs growth, increases skeletal disproportionality, and adversely affects neurocranial development. Early initiation of therapy-ideally within the first 3 months-is essential. These findings highlight the need for newborn screening in India.
Kochar et al. (Wed,) studied this question.